Last reviewed · How we verify
Vabysmo (FARICIMAB)
Vabysmo works by blocking the activity of a protein called vascular endothelial growth factor A.
Vabysmo (FARICIMAB) is a small molecule developed by Genentech Inc, targeting vascular endothelial growth factor A. It is approved for the treatment of exudative age-related macular degeneration and macular edema due to diabetes mellitus. Vabysmo works by inhibiting the activity of vascular endothelial growth factor A, which is involved in the growth of new blood vessels and the leakage of fluid from blood vessels. The commercial status of Vabysmo is patented, and it was FDA-approved in 2022. Key safety considerations include the potential for increased risk of intraocular inflammation and retinal vasculitis.
At a glance
| Generic name | FARICIMAB |
|---|---|
| Sponsor | Roche |
| Target | Vascular endothelial growth factor A |
| Modality | Monoclonal antibody |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2022 |
| Annual revenue | 5500 |
Mechanism of action
Faricimab is humanized bispecific antibody that acts through inhibition of two pathways by binding to VEGF-A and Ang-2. By inhibiting VEGF-A, faricimab suppresses endothelial cell proliferation, neovascularization and vascular permeability. By inhibiting Ang-2, faricimab is thought to promote vascular stability and desensitize blood vessels to the effects of VEGF-A. Ang-2 levels are increased in some patients with nAMD and DME. The contribution of Ang-2 inhibition to the treatment effect and clinical response for nAMD and DME has yet to be established.
Approved indications
- Exudative age-related macular degeneration
- Macular edema due to diabetes mellitus
Common side effects
- Conjunctival hemorrhage
- Vitreous floaters
- Intraocular pressure increased
- Eye pain
- Intraocular inflammation
- Eye irritation
- Ocular discomfort
- Vitreous hemorrhage
- Corneal abrasion
- Eye pruritus
- Lacrimation increased
- Ocular hyperemia
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Safety and Efficacy of Faricimab in Patients With NPDR (PHASE2)
- A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324 (PHASE1)
- A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME) (PHASE1)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia (PHASE3)
- A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vabysmo CI brief — competitive landscape report
- Vabysmo updates RSS · CI watch RSS
- Roche portfolio CI